RMAT designation is a significant regulatory milestone that de-risks lasme-cel's development path and provides potential for expedited review. The upcoming EHA data presentation on June 13 is a key catalyst — positive data could drive further upside. Monitor enrollment updates for the pivotal Phase 2 trial and any partnership or financing announcements given the company's clinical-stage status.
Price Chart
Executive Summary
Cellectis announced FDA Regenerative Medicine Advanced Therapy (RMAT) designation for lasme-cel, its allogeneic CAR-T therapy for relapsed/refractory B-ALL. The designation, supported by Phase 1 BALLI-01 data, provides expedited development and regulatory benefits. Final Phase 1 data will be presented at EHA on June 13, 2026.
Key Facts
- FDA granted RMAT designation to lasme-cel (CD22-targeting allogeneic CAR-T) for r/r B-ALL
- RMAT designation is supported by Phase 1 BALLI-01 data showing promising efficacy and manageable safety
- Final Phase 1 data to be presented in oral session at EHA on June 13, 2026
- Pivotal Phase 2 BALLI-01 trial is open for enrollment
- First allogeneic CAR-T therapy to receive RMAT designation in a pivotal trial for r/r B-ALL
Financial Impact
No financial figures provided in filing; RMAT designation can accelerate development and reduce regulatory risk, potentially increasing probability of approval and commercial value of lasme-cel
Risk Factors
- RMAT designation can be revoked if criteria are no longer met
- Phase 1 data may not be replicated in larger pivotal Phase 2 trial
- Clinical-stage biotech with no approved products; regulatory approval not guaranteed
- Potential need for additional capital to fund development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004006 |
| Document: f6k_060926.htm | 0001171843-26-004006 |
| Document: 0001171843-26-004006-index-headers.html | 0001171843-26-004006 |
| Document: 0001171843-26-004006-index.html | 0001171843-26-004006 |
| Document: 0001171843-26-004006.txt | 0001171843-26-004006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 6-K | $1.83 | awaiting T+60 | — | $0.9800 (+46.45%) |
Sep 11, 2026 6w ago | Press Release | $1.83 | awaiting T+60 | — | $0.9800 (−46.45%) |
Aug 6, 2026 11w ago | Press Release | $2.84 | awaiting T+60 | — | $0.9800 (−65.43%) |
Jun 29, 2026 17w ago | Court Ruling | $3.00 $1.43 | ▼ −52.33% | ▼ −55.32% | $0.9800 (−67.33%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9800 (−65.37%) |
Jun 25, 2026 17w ago | 6-K | $2.83 $1.51 | ▼ −46.64% | ▼ −52.75% | $0.9800 (−65.37%) |
Jun 11, 2026 19w ago | Press Release | $3.09 $3.24 | ▲ +4.85% | ▲ +0.46% | $0.9800 (−68.28%) |
Jun 9, 2026 19w ago | 6-K | $3.18 $3.32 | ▲ +4.40% | ▼ −2.18% | $0.9800 (−69.18%) |
May 12, 2026 23w ago | 6-K | $3.96 $2.69 | ▼ −32.07% | ▼ −36.45% | $0.9800 (−75.25%) |
May 4, 2026 25w ago | 6-K | $3.76 $2.85 | ▼ −24.20% | ▼ −26.94% | $0.9800 (−73.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers